🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

247 results for “Pari Pharma GmbH” Clear

  1. PROGRAF 5 mg, gélule, PROGRAF 1 mg, gélule, IMUREL 25 mg, comprimé pelliculé, CYCLOPHOSPHAMIDE, PROGRAF 0,5 mg, gélule

    Pari Pharma GmbH

    Antisynthetase syndrome-related interstitial lung disease

    phase 3 small molecule active

    1 trial

  2. PROPRANOLOL

    Pari Pharma GmbH

    Von Hippel-Lindau (VHL) disease

    phase 3 small molecule active

    1 trial

  3. PROTAMINE CHOAY 1000 U.A.H./ml, solution injectable

    Pari Pharma GmbH

    Any patients ≥18 years old, eligible for transfemoral TAVI with coverage for medical insurance

    phase 3 small molecule active

    1 trial

  4. Placebo ADCETRIS ( NaCl 0.9% 100 mL - Injection IV ), ADCETRIS 50 mg powder for concentrate for solution for infusion.

    Pari Pharma GmbH

    rare disease

    phase 3 small molecule active

    1 trial

  5. Placebo IRBESARTAN EG 150 mg, Irbesartan EG 150 mg comprimés pelliculés

    Pari Pharma GmbH

    Acute kidney injury

    phase 3 small molecule active

    1 trial

  6. Placebo de PREDNISONE ARROW 20 mg, PREDNISONE ARROW 20 mg, comprimé sécable

    Pari Pharma GmbH

    Septic arthritis

    phase 3 small molecule active

    1 trial

  7. Placebo de fasturtec, Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion.

    Pari Pharma GmbH

    Patients hospitalised in intensive care, diagnosed with sepsis less than 48 hours ago, uric acid level ≥200µmol/L, adults, negative G6PD deficiency

    phase 3 small molecule active

    1 trial

  8. Placebo de formule développée spécifiquement pour la recherche par la PUI (cf IMPD-Q), CLOBETASOL PROPIONATE

    Pari Pharma GmbH

    Adult patients with symptomatic and inflammatory Hand osteoarthritis HOA.

    phase 3 small molecule active

    1 trial

  9. Placebo double encapsulated oral transplant of fecal microbiota, Double encapsulated oral transplant of fecal microbiota

    Pari Pharma GmbH

    Adults Non Diabete Remission (NDR) Type 2 Diabete (T2D) patients 1 to 5 years after bariatric surgery

    phase 3 small molecule active

    1 trial

  10. Placebo double encapsulated oral transplant of fecal microbiota, Double encapsulated oral transplant of fecal microbiota

    Pari Pharma GmbH

    Patients colonized with MDR-GNB

    phase 3 small molecule active

    1 trial

  11. Placebo du FORXIGA 10 mg, Forxiga 10 mg film-coated tablets

    Pari Pharma GmbH

    Adult patients discharged alive from ICU with a decreased eGFR, and/or an AKI during ICU stay and/or an elevated NT-proBNP at discharge.

    phase 3 small molecule active

    1 trial

  12. Placebo of Eliquis 2.5 mg, Eliquis 2.5 mg film-coated tablets

    Pari Pharma GmbH

    Intrahepatic non-cirrhotic portal hypertension

    phase 3 small molecule active

    1 trial

  13. Placebo of Procoralan 5 mg, Procoralan 5 mg film-coated tablets

    Pari Pharma GmbH

    Septic shock

    phase 3 small molecule active

    1 trial

  14. Placebo of XEOMIN 100UY, powder for injection, XEOMIN 100 unités, poudre pour solution injectable

    Pari Pharma GmbH

    incisional hernia

    phase 3 small molecule active

    1 trial

  15. Placebo of ZIMINO (glucose 5%), ZIMINO 2,5 mg/ml, solution à diluer pour perfusion

    Pari Pharma GmbH

    Patients referred for an isolated or a combined surgical correction of functional moderate to severe tricuspid regurgitation

    phase 3 small molecule active

    1 trial

  16. RAPIBLOC 300 mg, poudre pour solution pour perfusion

    Pari Pharma GmbH

    Patients with microcirculatory abnormalities during septic shock

    phase 3 small molecule active

    1 trial

  17. REVERPLEG 40 U.I./2 mL, solution à diluer pour perfusion, NORADRENALINE VIATRIS 2 mg/ml SANS SULFITES, solution à diluer pour perfusion

    Pari Pharma GmbH

    Acute Kidney Injury, Liver transplantation

    phase 3 small molecule active

    1 trial

  18. RITUXIMAB, METHOTREXATE, MYCOPHENOLATE MOFETIL, RoActemra 162 mg solution for injection in pre-filled pen., AZATHIOPRINE, XELJANZ 5 mg film-coated tablets

    Pari Pharma GmbH

    Patients with GPA and inadequate response to standard of care therapy defined as an inadequate response to either a combination of glucocorticoids plus cyclophosphamide AND/OR a combination of glucocorticoids plus rituximab.

    phase 3 small molecule active

    1 trial

  19. Remyelination in Multiple Sclerosis: a PET-MR longitudinal study investigating individual profiles of myelin repair and the contribution of neuroinflammation (SMART in MS)

    Pari Pharma GmbH

    Remyelination in Multiple Sclerosis

    phase 3 other active

    1 trial

  20. Revatio 0.8 mg/ml solution for injection

    Pari Pharma GmbH

    Hypoxic ischemic encephalopathy

    phase 3 small molecule active

    1 trial

  21. RoActemra 20 mg/mL concentrate for solution for infusion, Tofidence 20 mg/mL concentrate for solution for infusion, Avtozma 20 mg/mL concentrate for solution for infusion., SODIUM CHLORIDE, Tyenne 20 mg/ml concentrate for solution for infusion

    Pari Pharma GmbH

    Chondrocalcinosis

    phase 3 small molecule active

    1 trial

  22. SARCLISA 20mg/mL concentrate for solution for infusion., Iclusig 15 mg film-coated tablets, SARCLISA 20mg/mL concentrate for solution for infusion., BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion.

    Pari Pharma GmbH

    Patients aged 18-65 years old with newly diagnosed previously untreated ALL or T-LL.

    phase 3 small molecule active

    1 trial

  23. SODIUM CHLORIDE, Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)

    Pari Pharma GmbH

    HPV vaccine

    phase 3 small molecule active

    1 trial

  24. SODIUM CHLORIDE, HYDROCORTISONE UPJOHN 100 mg, préparation injectable, Placebo of hydrocortisone 100 mg, Reverpleg 40 U.I./2 ml solution à diluer pour perfusion

    Pari Pharma GmbH

    Adult cardiac arrest patients with sustained ROSC and hemodynamic failure due to post-resuscitation syndrome

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources